BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...of its internal RSV vaccine mRNA-1345, which it will evaluate in adults and children.BARDA awards Vaxxas...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...IV formulation of ofatumumab is approved as Arzerra to treat CLL. Merck exercises option for Vaxxas...
...develop and commercialize an undisclosed vaccine using the High-Density Microarray Patch (HD-MAP) platform from Vaxxas Pty. Ltd. Vaxxas...
...lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck & Co. Inc. Vaxxas Pty. Ltd. Aveo...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

...Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday...
...vaccines can be stored at 40°C for at least 12 months. Also on Tuesday, a Vaxxas-led...
...which delivers six times more antigen -- from the CSL Ltd. unit Seqirus Pty Ltd. Vaxxas...
BioCentury | Feb 16, 2015
Financial News

Vaxxas completes venture financing

Vaxxas Pty. Ltd. , Sydney, Australia Business: Drug delivery, Infectious Date completed: 2015-02-09 Type: Venture financing Raised: $20 million Investors: OneVentures; new investors; existing investors WIR Staff...
BioCentury | Feb 10, 2015
Financial News

Vaxxas raises $20M in B round

...of its needle-free Nanopatch technology to deliver an approved flu vaccine with an undisclosed partner. Vaxxas...
...World Health Organization to perform preclinical studies using Nanopatch to deliver polio vaccine. In 2012 Vaxxas...
...two additional undisclosed vaccine candidates (see BioCentury Extra, Oct. 8, 2012) . Several investors in Vaxxas'...
BioCentury | Oct 14, 2013
Strategy

Reviving Merck

...human antibody candidates, potentially including bispecific antibody candidates, across all disease areas (deal expansion) Jan-13 Vaxxas Pty. Ltd....
BioCentury | Oct 15, 2012
Company News

Vaxxas, Merck deal

...Vaxxas granted Merck exclusive, worldwide rights to develop and commercialize an undisclosed Merck vaccine using Vaxxas'...
...funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. Separately, Vaxxas...
...first CEO. Hoey was most recently VP of business development at PathoGenetiX Inc. (Woburn, Mass.). Vaxxas Pty. Ltd....
BioCentury | Oct 9, 2012
Company News

Vaxxas, Merck in vaccine deal

...Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide rights to develop and commercialize a vaccine using Vaxxas'...
...funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. Separately, Vaxxas...
BioCentury | Aug 15, 2011
Finance

Validating Vaxxas

...Australian investment in new vaccine company Vaxxas Pty Ltd. The Cambridge, Mass., firm participated in Vaxxas'...
...Brandon Capital Partners; the Medical Research Commercialization Fund (MRCF); and the Brisbane Angels also participated. Vaxxas...
...board, along with Paul Kelly of OneVentures and Stephen Thompson of Brandon Capital. Onsi said Vaxxas...
BioCentury | Aug 8, 2011
Financial News

Vaxxas completes venture financing

Vaxxas Pty. Ltd. , Brisbane, Australia Business: Drug delivery, Infectious Date completed: 8/1/11 Type: Venture financing Raised: A$15 million (US$16.6 million) Investors: OneVentures; Brandon Capital Partners; Medical Research Commercialization Fund; Brisbane Angels; HealthCare Ventures WIR Staff...
Items per page:
1 - 10 of 11
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...of its internal RSV vaccine mRNA-1345, which it will evaluate in adults and children.BARDA awards Vaxxas...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...IV formulation of ofatumumab is approved as Arzerra to treat CLL. Merck exercises option for Vaxxas...
...develop and commercialize an undisclosed vaccine using the High-Density Microarray Patch (HD-MAP) platform from Vaxxas Pty. Ltd. Vaxxas...
...lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck & Co. Inc. Vaxxas Pty. Ltd. Aveo...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

...Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday...
...vaccines can be stored at 40°C for at least 12 months. Also on Tuesday, a Vaxxas-led...
...which delivers six times more antigen -- from the CSL Ltd. unit Seqirus Pty Ltd. Vaxxas...
BioCentury | Feb 16, 2015
Financial News

Vaxxas completes venture financing

Vaxxas Pty. Ltd. , Sydney, Australia Business: Drug delivery, Infectious Date completed: 2015-02-09 Type: Venture financing Raised: $20 million Investors: OneVentures; new investors; existing investors WIR Staff...
BioCentury | Feb 10, 2015
Financial News

Vaxxas raises $20M in B round

...of its needle-free Nanopatch technology to deliver an approved flu vaccine with an undisclosed partner. Vaxxas...
...World Health Organization to perform preclinical studies using Nanopatch to deliver polio vaccine. In 2012 Vaxxas...
...two additional undisclosed vaccine candidates (see BioCentury Extra, Oct. 8, 2012) . Several investors in Vaxxas'...
BioCentury | Oct 14, 2013
Strategy

Reviving Merck

...human antibody candidates, potentially including bispecific antibody candidates, across all disease areas (deal expansion) Jan-13 Vaxxas Pty. Ltd....
BioCentury | Oct 15, 2012
Company News

Vaxxas, Merck deal

...Vaxxas granted Merck exclusive, worldwide rights to develop and commercialize an undisclosed Merck vaccine using Vaxxas'...
...funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. Separately, Vaxxas...
...first CEO. Hoey was most recently VP of business development at PathoGenetiX Inc. (Woburn, Mass.). Vaxxas Pty. Ltd....
BioCentury | Oct 9, 2012
Company News

Vaxxas, Merck in vaccine deal

...Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide rights to develop and commercialize a vaccine using Vaxxas'...
...funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. Separately, Vaxxas...
BioCentury | Aug 15, 2011
Finance

Validating Vaxxas

...Australian investment in new vaccine company Vaxxas Pty Ltd. The Cambridge, Mass., firm participated in Vaxxas'...
...Brandon Capital Partners; the Medical Research Commercialization Fund (MRCF); and the Brisbane Angels also participated. Vaxxas...
...board, along with Paul Kelly of OneVentures and Stephen Thompson of Brandon Capital. Onsi said Vaxxas...
BioCentury | Aug 8, 2011
Financial News

Vaxxas completes venture financing

Vaxxas Pty. Ltd. , Brisbane, Australia Business: Drug delivery, Infectious Date completed: 8/1/11 Type: Venture financing Raised: A$15 million (US$16.6 million) Investors: OneVentures; Brandon Capital Partners; Medical Research Commercialization Fund; Brisbane Angels; HealthCare Ventures WIR Staff...
Items per page:
1 - 10 of 11